NCT06897748 - A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 12, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Placebo

Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study

DRUG

Tozorakimab

Administered subcutaneously tozorakimab and placebo throughout the study

Trial Locations (13)

105554

RECRUITING

Research Site, Moscow

117546

SUSPENDED

Research Site, Moscow

119048

RECRUITING

Research Site, Moscow

125284

RECRUITING

Research Site, Moscow

193231

RECRUITING

Research Site, Saint Petersburg

410053

SUSPENDED

Research Site, Saratov

410054

RECRUITING

Research Site, Saratov

426061

RECRUITING

Research Site, Izhevsk

432009

RECRUITING

Research Site, Ulyanovsk

440067

RECRUITING

Research Site, Penza

614000

RECRUITING

Research Site, Perm

624002

RECRUITING

Research Site, Aramil

644099

RECRUITING

Research Site, Omsk